Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | THPO | P40225 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740975 | 0.90 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL16740976 | 0.90 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2580815 | 0.90 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2585392 | 0.86 | ADK (0.46) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2583058 | 0.86 | LMNA (0.51) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL13714458 | 0.85 | LMNA (0.50) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL13205000 | 0.85 | LMNA (0.50) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL10271535 | 0.84 | LMNA (0.49) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2584902 | 0.84 | DNMT1 (0.49) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2587208 | 0.84 | ALB (0.51) | LMNAALDH1A1HTTMTORTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| CN-1646141-B | Modified nucleosides for treating viral infections and abnormal cell proliferation | PHARMASSET LTD | 2014-06-25 | — | — | CN | disclosed |
| CN-101862345-B | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation | GILEAD SCIENCES INC | 2014-06-04 | — | — | CN | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| CN-101862345-A | The modified nucleosides that is used for the treatment of viral infection and abnormal cell proliferation | PHARMASSET LTD | 2010-10-20 | — | — | CN | disclosed |
| CN-1646141-A | Modified nucleosides for treating viral infections and abnormal cell proliferation | PHARMASSET LTD (BB) | 2005-07-27 | — | — | CN | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | LMNA 1019/4885ALDH1A1 1466/4885HTT 4480/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | LMNA 694/4885ALDH1A1 2416/4885HTT 4766/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | LMNA 821/4885ALDH1A1 1128/4885HTT 4514/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | LMNA 1076/4885ALDH1A1 1367/4885HTT 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.